Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Published:2022-08 Issue:8 Volume:21 Page:693-703
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Svenningsson Anders,Frisell Thomas,Burman Joachim,Salzer Jonatan,Fink Katharina,Hallberg Susanna,Hambraeus Joakim,Axelsson Markus,Nimer Faiez Al,Sundström Peter,Gunnarsson Martin,Johansson Rune,Mellergård Johan,Rosenstein Igal,Ayad Ahmad,Sjöblom Irina,Risedal Anette,de Flon Pierre,Gilland Eric,Lindeberg Jonas,Shawket Fadi,Piehl Fredrik,Lycke Jan

Funder

Vetenskapsrådet

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference29 articles.

1. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis;Hauser;N Engl J Med,2008

2. Ocrelizumab versus Interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017

3. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden—outlier or predecessor?;Berntsson;Acta Neurol Scand,2018

4. Ofatumumab versus teriflunomide in multiple sclerosis;Hauser;N Engl J Med,2020

5. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis;Granqvist;JAMA Neurol,2018

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of high efficacy therapies in older people with Multiple Sclerosis: A real-world evidence study;Multiple Sclerosis and Related Disorders;2024-10

2. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects;Pharmacological Reports;2024-08-23

3. A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis;Cell Metabolism;2024-08

4. Successful treatment of relapsed and refractory CIDP with ofatumumab: a first case report;Frontiers in Immunology;2024-07-31

5. Long-term use of rituximab increases T cell count in MS patients;Frontiers in Immunology;2024-07-17